Bristol-Myers Squibb (BMY) Cash Flow Statement

Click line-items for a historical chart and %

Cash Flows From Operating Activities:
Net Earnings	3.61B
Adjustments to reconcile net earnings to net cash provided by operating activities:
Net earnings attributable to noncontrolling interest
Depreciation
Amortization
Impairment charges	75M
Deferred income tax expense	-500M
Stock-based compensation expense	149M
Other adjustments	-56M
Changes in operating assets and liabilities:
Receivables	-896M
Inventories	-107M
Accounts payable	-142M
Deferred income
U.S. and foreign income taxes payable	-262M
Other	-467M
Net Cash Provided by Operating Activities	1.42B
Cash Flows From Investing Activities:
Proceeds from sale and maturities of marketable securities	3.67B
Purchases of marketable securities	-2.25B
Additions to property, plant and equipment and capitalized software	-844M
Proceeds from sale of businesses and other investing activities	1.19B
Proceeds from sale of businesses and other investing activities
Net Cash Used in Investing Activities	1.46B
Cash Flows From Financing Activities:
Short-term debt borrowings/(repayments)	102M
Long-term debt borrowings	0
Long-term debt repayments	0
Interest rate swap terminations
Issuances of common stock
Common stock repurchases	-231M
Dividends paid	-1.91B
Net Cash Used in Financing Activities	-1.86B
Effect of Exchange Rates on Cash and Cash Equivalents	16M
(Decrease)/Increase in Cash and Cash Equivalents	1.05B
Cash and Cash Equivalents at Beginning of Period	2.39B
Cash and Cash Equivalents at End of Period	3.43B

Entities mentioned with BMY